Nirmatrelvir (PF-07321332) is an orally bioavailable 3C-like protease (3CL) inhibitor that is the subject of clinical trial NCT04756531. 3CL is responsible for cleaving polyproteins 1a and 1ab of SARS-CoV-2. Without the activity of the SARS-CoV-2 3CL, nonstructural proteins (including proteases) cannot be released to perform their functions, inhibiting viral...
In the US, Europe, and Canada, nirmatrelvir, in combination with ritonavir, is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID-19, including hospitalization or death. In Europe, this therapeutic indication is approved under conditional marketing authorization.
Yale University, New Haven, Connecticut, United States
Stanford University, Stanford, California, United States
University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States
Mercury Street Medical Group, PLLC, Butte, Montana, United States
Global Health Clinical Trials, Miami, Florida, United States
Multiprofile Hospital for Active Treatment - Sveti Nikolay Chudotvoretz, Lom, Montana, Bulgaria
Specialized Hospital for Active Treatment of Pneumo-Phthisiatric Diseases - Haskovo EOOD, Haskovo, Bulgaria
"University Multiprofile Hospital for Active Treatment - Dr. Georgi Stranski" EAD, Pleven, Bulgaria
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
Diex Recherche Sherbrooke Inc., Sherbrooke, Quebec, Canada
Emory University School of Medicine, Atlanta, Georgia, United States
IBPClin - Instituto Brasil de Pesquisa ClÃnica, Rio de Janeiro, Brazil
University of Alabama at Birmingham Women & Infant Center, Birmingham, Alabama, United States
University of Alabama at Birmingham/Center for Women's Reproductive Health, Birmingham, Alabama, United States
Abby's Research institute, Phoenix, Arizona, United States
University of Alabama at Birmingham - School of Medicine, Birmingham, Alabama, United States
Phoenix Children's Hospital, Phoenix, Arizona, United States
Arkansas Children's Hospital, Little Rock, Arkansas, United States
Sukraraj Tropical & Infectious Disease Hospital, Kathmandu, Nepal
Universidade Federal de Minas Gerais, Minas Gerais, Brazil
Laos-Oxford-Mahosot Wellcome Trust Research Unit, Vientiane, Lao People's Democratic Republic
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.